Pazan, Farhad
Breunig, Hanna
Weiss, Christel
Röhr, Susanne
Luppa, Melanie
Pentzek, Michael
Bickel, Horst
Weeg, Dagmar
Weyerer, Siegfried
Wiese, Birgitt
König, Hans-Helmut
Brettschneider, Christian
Heser, Kathrin
Maier, Wolfgang
Scherer, Martin
Riedel-Heller, Steffi
Wagner, Michael
Wehling, Martin http://orcid.org/0000-0003-1393-1691
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung
Medizinische Fakultät Mannheim der Universität Heidelberg
Article History
Received: 4 March 2022
Accepted: 7 September 2022
First Online: 27 September 2022
Declarations
:
: Martin W. was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Bristol Myers, Bayer, Boehringer-Ingelheim, LEO, Mundipharma, Novartis, Pfizer, Polyphor, Helsinn, Allergan, Allecra, Novo-Nordisk, Heel, AstraZeneca, Roche, Santhera, Sanofi-Aventis, Shire, Berlin-Chemie, and Daichii-Sankyo. Farhad P., Hanna B., Christel W., Kathrin H., Susanne R., Birgitt W., Siegfried W., Hans-Helmut K., Christian B., Melanie L., Horst B., Michael P., Wolfgang M., Martin S., Dagmar W., Steffi R.-H., and Michael W. have no COIs to declare.